Menu
ÚHKT

doc. Mgr. Kateřina Machová Poláková, Ph.D.

vedoucí oddělení molekulární genetiky

Tel: +420 221 977 305
Email: Katerina.Machova@uhkt.cz

Impaktované publikace

[1]

Saussele, S.; Richter, J.; Guilhot, J.; Gruber, F.X.; Hjorth-Hansen, H.; Almeida, A.; Janssen, J.J.W.M.; Mayer, J.; Koskenvesa, P.; Panayiotidis, P.; Olsson-Strömberg, U.; Martinez-Lopez, J.; Rousselot, P.; Vestergaard, H.; Ehrencrona, H.; Kairisto, V.; Machová Poláková, K.; Müller, M.C.; Mustjoki, S.; Berger, M.G.; Fabarius, A.; Hofmann, W.-K.; Hochhaus, A.; Pfirrmann, M.; Mahon, F.-X.; Ossenkoppele, G.; Pagoni, M.N.; Söderlund, S.; Escoffre-Barbe, M.; Etienne, G.; Dengler, J.; Huguet, F.; von Bubnoff, N.; Klamova, H.

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

[rok vydání 2018, impact factor 35.386 ]

[2]

Musilova, K.; Devan, J.; Cerna, K.; Seda, V.; Pavlasova, G.; Sharma, S.; Oppelt, J.; Pytlik, R.; Prochazka, V.; Prouzova, Z.; Trbusek, M.; Zlamalikova, L.; Liskova, K.; Kruzova, L.; Jarosova, M.; Mareckova, A.; Kornauth, C.; Simonitsch-Klupp, I.; Schiefer, A.-I.; Merkel, O.; Mocikova, H.; Burda, P.; Polakova, K.M.; et al.

miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels

[rok vydání 2018, impact factor 16.562 ]

[3]

Hovorkova, L.; Zaliova, M.; Venn, N.C.; Bleckmann, K.; Trkova, M.; Potuckova, E.; Vaskova, M.; Linhartova, J.; Machova Polakova, K.; Fronkova, E.; Muskovic, W.; Giles, J.E.; Shaw, P.J.; Cario, G.; Sutton, R.; Stary, J.; Trka, J.; Zuna, J.

Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology

[rok vydání 2017, impact factor 15.132 ]

[4]

Cross, N.C.; White, H.E.; Colomer, D.; Ehrencrona, H.; Foroni, L.; Gottardi, E.; Lange, T.; Lion, T.; Machova Polakova, K.; Dulucq, S.; Martinelli, G.; Oppliger Leibundgut, E.; Pallisgaard, N.; Barbany, G.; Sacha, T.; Talmaci, R.; Izzo, B.; Saglio, G.; Pane, F.; Müller, M.C.; Hochhaus, A.

Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia

[rok vydání 2015, impact factor 12.104 ]

[5]

White, H.; Deprez, L.; Corbisier, P.; Hall, V.; Lin, F.; Mazoua, S.; Trapmann, S.; Aggerholm, A.; Andrikovics, H.; Akiki, S.; Barbany, G.; Boeckx, N.; Bench, A.; Catherwood, M.; Cayuela, J.-M.; Chudleigh, S.; Clench, T.; Colomer, D.; Daraio, F.; Dulucq, S.; Farrugia, J.; Fletcher, L.; Foroni, L.; Ganderton, R.; Gerrard, G.; Gineikiene, E.; Hayette, S.; El Housni, H.; Izzo, B.; Jansson, M.; Johnels, P.; Jurcek, T.; Kairisto, V.; Kizilors, A.; Kim, D.-W.; Lange, T.; Lion, T.; Polakova, K.M.; Martinelli, G.; McCarron, S.; Merle, P.A.; Milner, B.; Mitterbauer-Hohendanner, G.; Nagar, M.; Nickless, G.; Nomdedeu, J.; Nymoen, D.A.; Leibundgut, E.O.; Ozbek, U.; Pajic, T.; Pfeifer, H.; Preudhomme, C.; Raudsepp, K.; Romeo, G.; Sacha, T.; Talmaci, R.; Touloumenidou, T.; Van der Velden, V.H.J.; Waits, P.; Wang, L.; Wilkinson, E.; Wilson, G.; Wren, D.; Zadro, R.; Ziermann, J.; Zoi, K.; Muller, M.C.; Hochhaus, A.; Schimmel, H.; Cross, N.C.P.; Emons, H.

A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR

[rok vydání 2014, impact factor 12.104 ]

[6]

Cross, N.C.P.; White, H.E.; Ernst, T.; Welden, L.; Dietz, C.; Saglio, G.; Mahon, F.-X.; Wong, C.C.; Zheng, D.; Wong, S.; Wang, S.-S.; Akiki, S.; Albano, F.; Andrikovics, H.; Anwar, J.; Balatzenko, G.; Bendit, I.; Beveridge, J.; Boeckx, N.;Cerveira, N.; Cheng, S.-M.; Colomer, D.; Czurda, S.; Daraio, F.; Dulucq, S.; Eggen, L.; El Housni, H.; Gerrard, G.; Gniot, M.; Izzo, B.; Jacquin, D.; Janssen, J.J.W.M.; Jeromin, S.; Jurcek, T.; Kim, D.-W.; Machova-Polakova, K.; Martinez-Lopez, J.; McBean, M.; Mesanovic, S.; Mitterbauer-Hohendanner, G.; Mobtaker, H.; Mozziconacci, M.-J.; Pajič, T.; Pallisgaard, N.; Panagiotidis, P.; Press, R.D.; Qin, Y.-Z.; Radich, J.; Sacha, T.; Touloumenidou, T.; Waits, P.; Wilkinson, E.; Zadro, R.; Müller, M.C.; Hochhaus, A.; Branford, S.

Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale

[rok vydání 2016, impact factor 11.702 ]

[7]

Soverini, S.; De Benedittis, C.; Papayannidis, C.; Polakova, K.M.; Venturi, C.; Russo, D.; Bresciani, P.; Iurlo, A.; Mancini, M.; Vitale, A.; Chiaretti, S.; Foa, R.; Abruzzese, E.; Sora, F.; Kohlmann, A.; Haferlach, T.; Baccarani, M.; Cavo, M.; Martinelli, G.

Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients

[rok vydání 2016, impact factor 11.702 ]

[8]

Kramarzova, K.; Stuchly, J.; Willasch, A.; Gruhn, B.; Schwarz, J.; Cermak, J.; Machova-Polakova, K.; Fuchs, O.; Stary, J.; Trka, J.; Boublikova, L.

Real-time PCR quantification of major Wilms' tumor gene 1 (WT1) isoforms in acute myeloid leukemia, their characteristic expression patterns and possible functional consequences

[rok vydání 2012, impact factor 10.164 ]

[9]

Soverini, S.; De Benedittis, C.; Machova Polakova, K.; Brouckova, A.; Horner, D.; Iacono, M.; Castagnetti, F.; Gugliotta, G.; Palandri, F.; Papayannidis, C.; Iacobucci, I.; Venturi, C.; Bochicchio, M.T.; Klamova, H.; Cattina, F.; Russo, D.; Bresciani, P.; Binotto, G.; Giannini, B.; Kohlmann, A.; Haferlach, T.; Roller, A.; Rosti, G.; Cavo, M.; Baccarani, M.; Martinelli, G.

Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain

[rok vydání 2013, impact factor 9.775 ]

[10]

Machova Polakova, K.; Zizkova, H.; Zuna, J.; Motlova, E.; Hovorkova, L.; Gottschalk, A.; Glauche, I.; Koblihova, J.; Pecherkova, P.; Klamova, H.; Stastna Markova, M.; Srbova, D.; Benesova, A.; Polivkova, V.; et al.

Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission

[rok vydání 2020, impact factor 8.665 ]

[11]

Srutova, K.; Curik, N.; Burda, P.; Savvulidi, F.; Silvestri, G.; Trotta, R.; Klamova, H.; Pecherkova, P.; Sovova, Z.; Koblihova, J.; Stopka, T.; Perrotti, D.; Machova Polakova, K.

BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia

[rok vydání 2018, impact factor 7.570 ]

[12]

Jaruskova, M.; Curik, N.; Hercog, R.; Polivkova, V.; Motlova, E.; Benes, V.; Klamova, H.; Pecherkova, P.; Belohlavkova, P.; Vrbacky, F.; Machova Polakova, K.

Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment

[rok vydání 2017, impact factor 6.217 ]

[13]

Linhartova, J.; Hovorkova, L.; Soverini, S.; Benesova, A.; Jaruskova, M.; Klamova, H.; Zuna, J.; Machova Polakova, K.

Characterization of 46 patient-specific BCR-ABL1 fusions and detection of SNPs upstream and downstream the breakpoints in chronic myeloid leukemia using next generation sequencing

[rok vydání 2015, impact factor 5.888 ]

[14]

Soverini, S.; De Benedittis, C.; Machova Polakova, K.; Linhartova, J.; Castagnetti, F.; Gugliotta, G.; Papayannidis, C.; Mancini, M.; Klamova, H.; Salvucci, M.; Crugnola, M.; Iurlo, A.; Albano, F.; Russo, D.; Rosti, G.; Cavo, M.; Baccarani, M.; Martinelli, G.

Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients

[rok vydání 2016, impact factor 5.168 ]

[15]

Zackova, D.; Klamova, H.; Dusek, L.; Muzik, J.; Machova Polakova, K.; Moravcova, J.; Jurcek, T.; Dvorakova, D.; Racil, Z.; Pospisil, Z.; Oltova, A.; Michalova, K.; Brezinova, J.; Razga, F.; Doubek, M.; Cetkovsky, P.; Trneny, M.; Mayer, J.

Imatinib as the first line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: can we compare real life data to the results from clinical trials?

[rok vydání 2010, impact factor 4.671 ]

[16]

Machová Poláková, K.; Lopotová, T.; Klamová, H.; Burda, P.; Trněný, M.; Stopka, T.; Moravcová, J.

Expression patterns of microRNAs associated with CML phases and their disease related targets

[rok vydání 2011, impact factor 3.993 ]

[17]

Mobius, S.; Schenk, T.; Himsel, D.; Maier, J.; Franke, G.-N.; Saussele, S.; Pott, C.; Andrikovics, H.; Meggyesi, N.; Machova-Polakova, K.; Zizkova, H.; et al.

Results of the European survey on the assessment of deep molecular response in chronic phase CML patients during tyrosine kinase inhibitor therapy (EUREKA registry)

[rok vydání 2019, impact factor 3.656 ]

[18]

Pavlik, T.; Janousova, E.; Mayer, J.; Indrak, K.; Jarosova, M.; Klamova, H.; Zackova, D.; Voglova, J.; Faber, E.; Karas, M.; Machova Polakova, K.; Racil, Z.; Demeckova, E.; Demitrovicova, L.; Tothova, E.; Chudej, J.; Markuljak, I.; Cmunt, E.; Kozak, T.; Muzik, J.; Dusek, L.

Current survival measures reliably reflect modern sequential treatment in CML: correlation with prognostic stratifications

[rok vydání 2013, impact factor 3.477 ]

[19]

Soverini, S.; De Benedittis, C.; Castagnetti F.; Gugliotta, G.; Mancini, M.; Bavaro, L.; Machova Polakova, K.; Linhartova, J.; Iurlo, A.; Russo, D.; Pane, F.; Saglio, G.; Rosti, G.; Cavo, M.; Baccarani, M.; Martinelli, G.

In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants

[rok vydání 2016, impact factor 3.288 ]

[20]

Preuner, S.; Barna, A.; Frommlet, F.; Czurda, S.; Konstantin, B.; Alikian, M.; Machova Polakova, K.; Sacha, T.; Richter, J.; Lion, T.; Gabriel, C.

Quantitative analysis of mutant subclones in chronic myeloid leukemia: comparison of different methodological approaches

[rok vydání 2016, impact factor 3.226 ]

Neimpaktované publikace

[1]

Machová Poláková, K.

MikroRNA u chronické myeloidní leukemie

[rok vydání 2013]